Examining Polyglutamine Peptide Length: a Connection Between Collapsed Conformations and Increased Aggregation

Overview

Journal J Mol Biol

Publisher Elsevier

Specialties Microbiology
Molecular Biology

Date 2009 Aug 25

PMID 19699209

Citations 63

Authors

Robert H Walters

Regina M Murphy

Affiliations

Soon will be listed here.

Abstract

Abnormally expanded polyglutamine domains in proteins are associated with several neurodegenerative diseases, of which the best known is Huntington's. Expansion of the polyglutamine domain facilitates aggregation of the affected protein, and several studies directly link aggregation to neurotoxicity. The age of onset of disease is inversely correlated with the length of the polyglutamine domain; this correlation motivates an examination of the role of the length of the domain on aggregation. In this investigation, peptides containing 8 to 24 glutamines were synthesized, and their conformational and aggregation properties were examined. All peptides lacked secondary structure. Fluorescence resonance energy transfer studies revealed that the peptides became increasingly collapsed as the number of glutamine residues increased. The effective persistence length was estimated to decrease from approximately 11 to approximately 7 A as the number of glutamines increased from 8 to 24. A comparison of our data with theoretical results suggests that phosphate-buffered saline is a good solvent for Q8 and Q12, a theta solvent for Q16, and a poor solvent for Q20 and Q24. By dynamic light scattering, we observed that Q16, Q20, and Q24, but not Q8 or Q12, immediately formed soluble aggregates upon dilution into phosphate-buffered saline at 37 degrees C. Thus, Q16 stands at the transition point between good and poor solvent and between stable and aggregation-prone peptide. Examination of aggregates by transmission electron microscopy, along with kinetic assays for sedimentation, provided evidence indicating that soluble aggregates mature into sedimentable aggregates. Together, the data support a mechanism of aggregation in which monomer collapse is accompanied by formation of soluble oligomers; these soluble species lack regular secondary structure but appear morphologically similar to the sedimentable aggregates into which they eventually mature.

Citing Articles

Intrinsic stiffness and -solvent regime in intrinsically disordered proteins: Implications for liquid-liquid phase separation.

Baidya L, Kremer K, Reddy G PNAS Nexus. 2025; 4(2):pgaf039.

PMID: 39980654 PMC: 11840863. DOI: 10.1093/pnasnexus/pgaf039.

Identifying Sequence Effects on Chain Dimensions of Disordered Proteins by Integrating Experiments and Simulations.

Holla A, Martin E, Dannenhoffer-Lafage T, Ruff K, Konig S, Nuesch M JACS Au. 2024; 4(12):4729-4743.

PMID: 39735932 PMC: 11672150. DOI: 10.1021/jacsau.4c00673.

Tracing the Evolutionary History of the Temperature-Sensing Prion-like Domain in EARLY FLOWERING 3 Highlights the Uniqueness of AtELF3.

Zhu Z, Trenner J, Delker C, Quint M Mol Biol Evol. 2024; 41(10).

PMID: 39391982 PMC: 11523139. DOI: 10.1093/molbev/msae205.

How hydrophobicity, side chains, and salt affect the dimensions of disordered proteins.

Baxa M, Lin X, Mukinay C, Chakravarthy S, Sachleben J, Antilla S Protein Sci. 2024; 33(5):e4986.

PMID: 38607226 PMC: 11010952. DOI: 10.1002/pro.4986.

Pathologic polyglutamine aggregation begins with a self-poisoning polymer crystal.

Kandola T, Venkatesan S, Zhang J, Lerbakken B, Von Schulze A, Blanck J Elife. 2023; 12.

PMID: 37921648 PMC: 10624427. DOI: 10.7554/eLife.86939.

References

Albrecht M, Golatta M, Wullner U, Lengauer T . Structural and functional analysis of ataxin-2 and ataxin-3. Eur J Biochem. 2004; 271(15):3155-70. DOI: 10.1111/j.1432-1033.2004.04245.x. View

Chen S, Ferrone F, Wetzel R . Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci U S A. 2002; 99(18):11884-9. PMC: 129363. DOI: 10.1073/pnas.182276099. View

Zhou H . Polymer models of protein stability, folding, and interactions. Biochemistry. 2004; 43(8):2141-54. DOI: 10.1021/bi036269n. View

Chen S, Berthelier V, Yang W, Wetzel R . Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol. 2001; 311(1):173-82. DOI: 10.1006/jmbi.2001.4850. View

Masino L, Kelly G, Leonard K, Trottier Y, Pastore A . Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett. 2002; 513(2-3):267-72. DOI: 10.1016/s0014-5793(02)02335-9. View

Dunn B, Pham C, Raney L, Abayasekara D, Gillespie W, Hsu A . Interaction of alpha-dansylated peptide inhibitors with porcine pepsin: detection of complex formation by fluorescence energy transfer and chromatography and evidence for a two-step binding scheme. Biochemistry. 1981; 20(25):7206-11. DOI: 10.1021/bi00528a023. View

Klein F, Pastore A, Masino L, Zeder-Lutz G, Nierengarten H, Oulad-Abdelghani M . Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient. J Mol Biol. 2007; 371(1):235-44. DOI: 10.1016/j.jmb.2007.05.028. View

Lee C, Walters R, Murphy R . Reconsidering the mechanism of polyglutamine peptide aggregation. Biochemistry. 2007; 46(44):12810-20. DOI: 10.1021/bi700806c. View

Ross C . Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron. 2002; 35(5):819-22. DOI: 10.1016/s0896-6273(02)00872-3. View

10.

Crick S, Jayaraman M, Frieden C, Wetzel R, Pappu R . Fluorescence correlation spectroscopy shows that monomeric polyglutamine molecules form collapsed structures in aqueous solutions. Proc Natl Acad Sci U S A. 2006; 103(45):16764-9. PMC: 1629004. DOI: 10.1073/pnas.0608175103. View

11.

Shao J, Diamond M . Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet. 2007; 16 Spec No. 2:R115-23. DOI: 10.1093/hmg/ddm213. View

12.

Singh V, Lapidus L . The intrinsic stiffness of polyglutamine peptides. J Phys Chem B. 2008; 112(42):13172-6. DOI: 10.1021/jp805636p. View

13.

Hyeon C, Thirumalai D . Kinetics of interior loop formation in semiflexible chains. J Chem Phys. 2006; 124(10):104905. DOI: 10.1063/1.2178805. View

14.

Ordway J, Gutekunst C, Bernstein E, Cearley J, Wiener H, Dure 4th L . Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell. 1997; 91(6):753-63. DOI: 10.1016/s0092-8674(00)80464-x. View

15.

Altschuler E, Hud N, MAZRIMAS J, Rupp B . Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. J Pept Res. 1997; 50(1):73-5. DOI: 10.1111/j.1399-3011.1997.tb00622.x. View

16.

Shen C, Fitzgerald M, Murphy R . Effect of acid predissolution on fibril size and fibril flexibility of synthetic beta-amyloid peptide. Biophys J. 1994; 67(3):1238-46. PMC: 1225480. DOI: 10.1016/S0006-3495(94)80593-4. View

17.

Schuler B, Lipman E, Steinbach P, Kumke M, Eaton W . Polyproline and the "spectroscopic ruler" revisited with single-molecule fluorescence. Proc Natl Acad Sci U S A. 2005; 102(8):2754-9. PMC: 549440. DOI: 10.1073/pnas.0408164102. View

18.

Zhang X, Smith D, Meriin A, Engemann S, Russel D, Roark M . A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2005; 102(3):892-7. PMC: 545525. DOI: 10.1073/pnas.0408936102. View

19.

Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, Regulier E . Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J Neurochem. 2007; 104(3):846-58. DOI: 10.1111/j.1471-4159.2007.05032.x. View

20.

Soranno A, Longhi R, Bellini T, Buscaglia M . Kinetics of contact formation and end-to-end distance distributions of swollen disordered peptides. Biophys J. 2009; 96(4):1515-28. PMC: 2717228. DOI: 10.1016/j.bpj.2008.11.014. View